Company: FENC
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001558370-25-005563
Chunk: 37

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 37
---
 | ​ |           112,600 |

| (1) | Calculated using the closing price of our Common Share on December 31, 2024 USD$6.32 on the Nasdaq which was the last trading day for the year 2024. |

| (2) | Awards listed for Mr. Raykov only include awards he received in his capacity as director (not as CEO). |

Director Incentive Plan Awards – Value Vested During the Year The following table details the value of director options on the vesting date that vested during 2024.

| ​                  | ​ |                 ​ | ​ | ​                         | ​ | ​                           |
| ​                  |   | Number of Options |   | Option-Based Awards       |   | Non-Equity Incentive Plan   |
| ​                  |   |            Vested |   | Value Vested              |   | Compensation – Value Earned |
| Name               | ​ |       During Year |   | During the Year (USD$)(1) |   | During the Year (USD$)      |
| Rosty Raykov       |   |                 — |   | —                         |   | —                           |
| Chris Rallis       |   |            20,000 |   | —                         |   | —                           |
| Dr. Khalid Islam   |   |            25,000 |   | —                         |   | —                           |
| Dr. Marco Brughera |   |            20,000 |   | —                         |   | —                           |
| Dr. Jodi Cook      |   |            20,000 |   | —                         |   | —                           |
| Total              |   |            85,000 |   | —                         |   | —                           |

Page24

| (1) | The value of the vested option-based awards represents the aggregate dollar value that would have been realized if the options under the option-based award had been exercised on the vesting date. The dollar value was computed by determining the difference between the closing market price of the Common Shares on the Nasdaq at the deemed exercise on the vesting date and the exercise price. |

Each non-management member receives an annual base retainer of $40,000. The Chairman of the Board shall receive an additional annual fee of $50,000 and includes all activities of the Chairman. The Chair of the Audit Committee receives an additional annual fee of $20,000. Chair of any other